Clinical efficacy of dacogen in myelodysplastic syndrome
https://doi.org/10.17650/1818-8346-2008-0-4-36-38
Abstract
Clinical efficiency of Dacogen (inhibitor of DNA hypermethylation) in 16 patients with MDS is presented. Bone marrow cytogenetic studies were performed in 6 patients; the detected chromosome aberrations included 5q deletion in 1 patient, X monosomy in 2 and multiple clonal rearrangements in 1. Results of this study indicated that after 4 courses of Dacogen (15mg/m2 i.v. 3 times daily for 3 days each course) significant clinical and hematological effects is received (according to standard criteria [1]): a complete response was in 3 patients; no partial response was registered; stabilization and bone marrow remission were achieved in 1 and 4 patients respectively. Response duration was 3.5 months. Drug myelotoxicity which would influence on intercourse interval and cause dose reduction during treatment was not revealed.
About the Authors
A. K. Golenkov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Moscow
G. A. Dudina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Moscow
I. V. Buravtsova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Moscow
E. V. Kataeva
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Moscow
N. V. Oparina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Moscow
References
1. Bennett J.M., Catorsky D., Danjel M.T. et al. Proposals for the myelodisplastic syndromes. Br J Haematal 1982;51:188—99.
2. Wardiman J.W., Harris N.L., Brunning R.D. The World Health (WHO) classification of the myeloid neoplasma. Blood 2002;100:2292—302.
3. Daskalakis M., Nguyen T.T., Guldberg P. et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’- deoxycytidine (decitabine) treatment. Blood 2002;100(8):2957—64.
4. De Vos D., van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005;84:3—8.
5. Kantarjian H.M., Issa J.-P., Rosenfeld C.S. et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006;106:1794—80.
6. Kantarjian H.M., O`Brein S., Shan J. et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109:265—73.
7. Kantarjian H.M., O`Brein S., Huang X. et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer 2007;109:1133—7.
Review
For citations:
Golenkov A.K., Dudina G.A., Buravtsova I.V., Kataeva E.V., Oparina N.V. Clinical efficacy of dacogen in myelodysplastic syndrome. Oncohematology. 2008;(4):36-38. (In Russ.) https://doi.org/10.17650/1818-8346-2008-0-4-36-38
Views:
159
Email this article 